ORKA
Oruka Therapeutics, Inc. Common StockORKA
ORKA
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
625% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 4
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
61% more funds holding
Funds holding: 41 [Q3] → 66 (+25) [Q4]
18.51% more ownership
Funds ownership: 70.17% [Q3] → 88.68% (+18.51%) [Q4]
0% more capital invested
Capital invested by funds: $604M [Q3] → $607M (+$2.45M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 4 [Q3] → 3 (-1) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
75%
upside
Avg. target
$33
184%
upside
High target
$45
293%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Mitchell Kapoor 31% 1-year accuracy 56 / 182 met price target | 293%upside $45 | Buy Reiterated | 7 Feb 2025 |
Wolfe Research Andy Chen 40% 1-year accuracy 6 / 15 met price target | 75%upside $20 | Outperform Initiated | 4 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 weeks ago
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year
Neutral
GlobeNewsWire
2 weeks ago
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
ORKA-001, targeting IL-23p19, Phase 1 trial ongoing, with pharmacokinetic (PK) data expected in 2H 2025 ORKA-001 Phase 2a initiation expected in 2H 2025, with efficacy readout in 2H 2026 that provides multiple opportunities to show differentiation over standard of care ORKA-002, targeting IL-17A/F, preclinical data to be presented at the 2025 AAD Annual Meeting; Phase 1 initiation expected in Q3 2025, with PK data in 1H 2026 Successful go-public transaction and over $475 million raised in 2024 $394 million of cash, cash equivalents, and marketable securities at year-end 2024, projected to fund company through 2027, over one year past anticipated ORKA-001 Phase 2a data in psoriasis MENLO PARK, Calif.,, March 06, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today reported fourth quarter and full year 2024 financial results and provided a corporate update.
Neutral
GlobeNewsWire
1 month ago
Oruka Therapeutics to Present at Multiple March Investor Conferences
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:
Neutral
GlobeNewsWire
3 months ago
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026 Preclinical data with ORKA-001 demonstrate the potential for once- or twice-yearly dosing, a significant improvement over standard of care MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it has initiated dosing of healthy volunteers in its first clinical trial of ORKA-001, the Company's novel, subcutaneously administered, half-life extended monoclonal antibody targeting IL-23p19.
Neutral
GlobeNewsWire
3 months ago
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Oruka's addition will become effective prior to market open on Monday, December 23rd, 2024.
Neutral
GlobeNewsWire
4 months ago
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Successful go-public transaction and over $475 million raised this year provides cash runway through multiple clinical inflection points
Neutral
GlobeNewsWire
4 months ago
Oruka Therapeutics to Present at Multiple November Investor Conferences
MENLO PARK, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced presentations at the following upcoming investor conferences:
Neutral
GlobeNewsWire
6 months ago
Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress
Half-life in non-human primates (NHP) of 30.3 days after subcutaneous (SQ) administration and 33.8 days after intravenous (IV) administration
Neutral
GlobeNewsWire
6 months ago
Oruka Therapeutics Announces $200 Million Private Placement
MENLO PARK, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka” or the “Company”) (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, including plaque psoriasis, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $200 million to the Company, before placement agent fees and offering expenses. The PIPE financing included participation from both new and existing investors, including a large investment manager, Braidwell LP, Venrock Healthcare Capital Partners, Fairmount, Access Biotechnology, Blackstone Multi-Asset Investing, Frazier Life Sciences, Paradigm BioCapital, RTW Investments LP, SR One, Janus Henderson Investors, Commodore Capital, Kalehua Capital, Avidity Partners, Affinity Healthcare Fund LP and Allostery Investments LP, among others.
Charts implemented using Lightweight Charts™